Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $35.67 Consensus Target Price from Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $35.67.

VIR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research note on Thursday, January 9th. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Thursday, February 27th. Barclays upped their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Leerink Partners raised their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, February 28th.

Insider Buying and Selling

In other news, EVP Verneuil Vanina De sold 7,373 shares of Vir Biotechnology stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares of the company’s stock, valued at $726,264.40. This trade represents a 8.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the sale, the director now directly owns 708,295 shares of the company’s stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,859 shares of company stock worth $326,458 over the last ninety days. Company insiders own 15.60% of the company’s stock.

Institutional Trading of Vir Biotechnology

A number of institutional investors have recently bought and sold shares of VIR. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Vir Biotechnology in the 4th quarter valued at approximately $42,000. SBI Securities Co. Ltd. acquired a new position in Vir Biotechnology in the 4th quarter valued at approximately $60,000. PNC Financial Services Group Inc. boosted its stake in shares of Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,999 shares during the last quarter. KBC Group NV boosted its stake in shares of Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after purchasing an additional 5,177 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new stake in shares of Vir Biotechnology in the 4th quarter valued at $74,000. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Price Performance

Shares of VIR opened at $7.37 on Tuesday. Vir Biotechnology has a 12 month low of $6.56 and a 12 month high of $14.45. The stock’s 50-day moving average is $9.53 and its two-hundred day moving average is $8.47. The stock has a market cap of $1.01 billion, a PE ratio of -1.88 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.09. The business had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. On average, research analysts anticipate that Vir Biotechnology will post -3.92 earnings per share for the current year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).